Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
8
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
europe blog main
europe top stories
8
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
fda
startups
alzheimer's disease
gilead sciences
cancer
cancer immunotherapy
deals
merck
philadelphia blog main
philadelphia top stories
abbvie
What
bio
roundup
8
×
cancer
acquisitions
amid
bombast
buy
caught
ceo
coronavirus
covid
daniel
days
debate
debut
develop
discussion
efforts
gilead
ipo
medicines
meso’s
miss
moves
o’day
pandemic
pfizer’s
presidential
promise
response
sciences
tuesday’s
vaccine
viewers
week
abbvie’s
activity
ahead
alliance
announced
Language
unset
Current search:
roundup
×
" europe top stories "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More